Sun Pharma Q4 Consol sales from operations up 11%
- May 31, 2022, 10.00 AM
- DealMoney News Service
Sun Pharmaceutical Industries Limited reported financials for the fourth quarter & full year ending March 31st, 2022.
The company's Consolidated sales from operations stood at Rs. 93,861 million, growth of 11% over Q4 last year.
India formulation sales was at Rs. 30,956 million, up 16% over same quarter last year, while US formulation sales was at US$ 389 million.
Dilip Shanghvi, Managing Director of the Company said, “FY22 was a good year with strong topline and EBITDA growth. All our geographies have recorded double digit growth and profitability has improved despite rising costs.The specialty business continues to ramp-up strongly with global Ilumya sales recording 81% growth to reach US$315 million in FY22.
Adjusted net profit for the quarter was at Rs. 15,821 million..
